China Resources Double-Crane Pharmaceutical ,Ltd. Receivables

China Resources Double-Crane Pharmaceutical ,Ltd. (600062.SS) currently reports a receivables of $3.6B as of June 2026. That compares with $3.1B in the prior-year period — up 15.0% year over year. Use the charts on this page to explore China Resources Double-Crane Pharmaceutical ,Ltd.'s receivables history and peer comparisons.

China Resources Double-Crane Pharmaceutical ,Ltd.'s receivables increased from $3.1B to $3.6B — a 15.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Resources Double-Crane Pharmaceutical ,Ltd. reported $3.6B in receivables as of June 2026. That compares with $3.1B in the prior-year period — up 15.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $3.6B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for China Resources Double-Crane Pharmaceutical ,Ltd., and consider following 600062.SS for alerts when major investors trade the stock.